CN1605334A - 组合物在制备用于治疗肿瘤疾病的药物中的用途 - Google Patents

组合物在制备用于治疗肿瘤疾病的药物中的用途 Download PDF

Info

Publication number
CN1605334A
CN1605334A CNA2004100032827A CN200410003282A CN1605334A CN 1605334 A CN1605334 A CN 1605334A CN A2004100032827 A CNA2004100032827 A CN A2004100032827A CN 200410003282 A CN200410003282 A CN 200410003282A CN 1605334 A CN1605334 A CN 1605334A
Authority
CN
China
Prior art keywords
general formula
day
compound
patients
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100032827A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦尼斯劳R·伯辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1605334A publication Critical patent/CN1605334A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
CNA2004100032827A 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途 Pending CN1605334A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
US09/121567 1998-07-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB99811314XA Division CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物

Publications (1)

Publication Number Publication Date
CN1605334A true CN1605334A (zh) 2005-04-13

Family

ID=22397538

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2004100032827A Pending CN1605334A (zh) 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途
CNB99811314XA Expired - Fee Related CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物
CNB2004100616005A Expired - Fee Related CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB99811314XA Expired - Fee Related CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物
CNB2004100616005A Expired - Fee Related CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100414587B1 (enExample)
CN (3) CN1605334A (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ATE311358T1 (de) * 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
EA202090024A1 (ru) * 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE69734713T2 (de) 1996-05-14 2006-07-06 Burzynski, Stanislaw R., Houston Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100417101B1 (ko) 2004-02-05
KR20010071025A (ko) 2001-07-28
EP1098643B1 (en) 2004-01-07
ZA200100622B (en) 2002-06-26
ID28160A (id) 2001-05-10
US6943192B2 (en) 2005-09-13
US20010044466A1 (en) 2001-11-22
EP1098643A2 (en) 2001-05-16
WO2000004894A3 (en) 2000-04-27
DK1098643T3 (da) 2004-05-24
NZ509244A (en) 2004-02-27
KR20030027087A (ko) 2003-04-03
AU4854299A (en) 2000-02-14
PL213698B1 (pl) 2013-04-30
US6258849B1 (en) 2001-07-10
BR9912356A (pt) 2001-04-17
WO2000004894A2 (en) 2000-02-03
KR100417100B1 (ko) 2004-02-05
IL140848A0 (en) 2002-02-10
EA200100168A1 (ru) 2001-08-27
DE69914084D1 (de) 2004-02-12
KR20030027089A (ko) 2003-04-03
CA2336945A1 (en) 2000-02-03
CN1660061A (zh) 2005-08-31
CN1319010A (zh) 2001-10-24
CA2336945C (en) 2008-11-18
KR100399658B1 (ko) 2003-09-29
DE69914084T2 (de) 2004-10-28
EA004179B1 (ru) 2004-02-26
PT1098643E (pt) 2004-05-31
KR20030027088A (ko) 2003-04-03
JP2011051993A (ja) 2011-03-17
CN1191064C (zh) 2005-03-02
ATE257378T1 (de) 2004-01-15
PL345959A1 (en) 2002-01-14
ES2214866T3 (es) 2004-09-16
JP2002521329A (ja) 2002-07-16
AU759278B2 (en) 2003-04-10
CN100400039C (zh) 2008-07-09
IL140848A (en) 2005-05-17
HK1037142A1 (en) 2002-02-01
KR100414587B1 (ko) 2004-01-13

Similar Documents

Publication Publication Date Title
CN1191064C (zh) 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物
US12186290B2 (en) Methods for the treatment of glioblastoma multiforme
CN1498103A (zh) 肽类化合物用于治疗非神经性炎性疼痛的新用途
CN1228694A (zh) 使用锰化合物降低抗肿瘤药物心脏毒性的方法
CN1531435A (zh) 抑制血管生成的方法
JP2012531405A (ja) 薬物嗜癖の治療および嗜癖関連行動を改善するための組成物
CN110339207B (zh) 抗癌剂的副作用的预防剂和/或治疗剂
CN101032475A (zh) 一种卡莫司汀的药用组合物、制备方法及用途
CN104105482B (zh) 红细胞生成素产生促进剂
CN1489460A (zh) 炎症性疾病治疗预防剂
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease
CA3133204A1 (en) Drug and method for treating or preventing diabetes complications using same drug
WO2015137383A1 (ja) 癌化学療法の補助剤
CN1620312A (zh) 慢性肾脏疾病治疗药物
EP4065129A1 (fr) Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
US20060205818A1 (en) Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CN1630533A (zh) 高血压症治疗药
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074771

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074771

Country of ref document: HK